Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2019)
•••
Post by Oden6570on Jun 20, 2021 6:29am
336 Views
Post# 33417612

I wonder what his yearly income is !

I wonder what his yearly income is ! Ashish M. Kamat is a consultant or advisory board member for Arquer Diagnostics, Asieris, Biological Dynamics, Bristol-Myers Squibb, CG Oncology, H3 Biomedicine/Eisai, Engene, FerGene, Imagin Medical, Janssen, Medac, Merck, Photocure, ProTara, Seattle Genetics, Sessen Bio, Theralase, US Biotest, and Urogen Inc; has received grant/research support from Adolor, AIBCCR, Bristol-Myers Squibb, FKD Industries, FerGene, Heat Biologics, Janssen (+ Taris), Merck, NIH/GU Specialized Programs of Research Excellence (SPORE), Photocure, Seattle Genetics, and SWOG; holds the patent for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); and is a board member for the International Bladder Cancer Group. Andrea Necchi is a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Ferring, GlaxoSmithKline, Incyte, Janssen, Merck, Rainier Therapeutics, Roche, and Seattle Genetics/Astellas; has received grant/research support from AstraZeneca, Ipsen, and Merck; and has received travel expenses/honoraria from AstraZeneca, Bristol-Myers Squibb, Foundation Medicine , Janssen, Merck, Rainier Therapeutics, and Roche.
Urologists, You’ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non–muscle-invasive Bladder Cancer - European Urology Oncology

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities